Helsinn Celebrates its 40th Anniversary

Lugano, Switzerland (ots/PRNewswire) -

~ 40 years helping patients achieve a better quality of life ~

Helsinn, the Swiss pharmaceutical Group focused on building
quality cancer care, is delighted to launch its 40th anniversary
celebrations in San Francisco, US, at the time of the JP Morgan 34th
Annual Healthcare Conference. Helsinn believes its core values of
respect, integrity and quality have underpinned four decades of
progress in helping patients enjoy a better quality of life, and is
delighted to be able to reaffirm those principles.

Riccardo Braglia, Vice Chairman and Helsinn Group CEO, commented
at the start of Helsinn's 40th anniversary year: "As cancer
treatments improve, enabling people to live longer, cancer is
becoming a 'chronic' disease. The need for products designed to
improve quality of life has never been more fundamental.

"Helsinn's cancer-care therapies have evolved in line with the
needs of people with cancer and have played a critical role in
shaping the supportive care market. For 40 years we have been
improving the everyday lives of patients, always guided by our core
family values of respect, integrity and quality. We maintain the
highest standards and provide world-class products and services that
improve health and quality of life for people affected by cancer
worldwide."

A family-owned business founded in 1976, Helsinn has been built
around a commitment to quality and innovation in cancer supportive
care and the management of other debilitating health conditions. Over
the past 40 years the medical and scientific communities have
progressively acknowledged the importance and benefits of managing
cancer symptoms and the secondary effects of cancer treatment
alongside the provision of core cancer therapies. Building on its
strong foundations, Helsinn now supports people with cancer in more
than 90 countries, through a network of over 70 trusted commercial
and marketing partners.

Working with these international partners, Helsinn has created a
successful portfolio of products that aims to improve the lives of
people with cancer. Alongside its partnering activities, Helsinn has
a high quality and growing R&D engine, from pre-clinical research
through all phases of clinical development with proven expertise and
focus in cancer care. In the last five years Helsinn has reinvested
an average of 30 per cent of its turnover each year on R&D and
Helsinn now has more than 600 committed employees globally, with a
presence in Switzerland, Ireland, US and China.

Helsinn, alongside its commercial and financial growth, puts great
emphasis on its employees, partners, stakeholders and the wider
community, and is committed to an ethical approach to business, built
around its family ethos. Helsinn's core values of respect, integrity
and quality are at the heart of everything the Company does. In 2015,
the Group was accredited with the CEO Gold Standard and its Global
Sustainability report was approved by Global Reporting Initiative
(GRI).

Since its inception, Helsinn has built a comprehensive portfolio
of market-leading products, such as Aloxi®, the market-leading
treatment for chemotherapy induced nausea and vomiting (CINV) and the
next generation Akynzeo®, the first approved fixed combination oral
agent that targets two critical signaling pathways associated with
CINV by combining netupitant, an NK1 receptor antagonist, and
palonosetron, a 5-HT3 receptor antagonist, in a single capsule for
the prevention of CINV. Akynzeo® has now been approved and is
marketed in both the US and Europe and more recently it has been
included as a treatment option in both the ASCO and NCCN anitemesis
guidelines.

In addition to standard of care drugs, Helsinn has an extensive
portfolio of internationally marketed therapies for indications
including oral mucositis, acute pain and primary dysmenorrhea,
osteoarthritis, adult rheumatoid arthritis, ankylosing spondylitis,
musculoskeletal and painful peri-articular disorders and gout.

Helsinn also has a broad pipeline of programs targeting other
unmet needs in cancer supportive care including chemotherapy-induced
diarrhea, cancer anorexia cachexia and chemotherapy-induced
neuropathic pain, metabolic conditions, and through its new Helsinn
Integrative Care division, non-pharmaceutical products and
treatments.

From its roots 40 years ago in a small office in Chiasso,
Switzerland, Helsinn is now not only providing the cancer supportive
care products that help people with debilitating and chronic diseases
around the world, but working with industry bodies and patient groups
to help educate health systems, doctors and patients to provide the
tools to improve the quality of life of people with cancer.

In 2016, our 40th anniversary year, you can meet representatives
from Helsinn at:

- JP Morgan Healthcare Conference (San Francisco, USA, 11-14 January)
- Informex (New Orleans, USA, 2-4 February)
- NCCN Annual Conference (Hollywood, FL, USA, 31 March-2 April)
- ASCO Annual Meeting (Chicago, USA, 3-7 June)
- MAASC Annual Meeting (Adelaide, Australia, 23-25 June)
- CPhI Worldwide (Barcelona, Spain, 4-6 October)
- ESMO Congress (Copenhagen, Denmark, 7-11 October)
- BioEurope (Köln, Germany, 4-6 November)

About Helsinn Group

Helsinn is a privately owned cancer supportive care pharmaceutical
group with an extensive portfolio of marketed products and a broad
development pipeline. Since 1976, Helsinn has been improving the
everyday lives of patients, guided by core family values of respect,
integrity and quality, through a unique integrated licensing business
model working with long standing partners in pharmaceuticals, medical
devices and nutritional supplement products. Helsinn is headquartered
in Lugano, Switzerland, with operating subsidiaries in Ireland and
the US (Helsinn Therapeutics), a representative office in China, as
well as a product presence in about 90 countries globally.

For more information, please visit http://www.helsinn.com.

ots Originaltext: Helsinn Healthcare SA
Im Internet recherchierbar: http://www.presseportal.de

Contact:
, please contact:
Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
PH +41-91-985-21-21
info-hhc@helsinn.com

For media / external enquiries
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Matthew Neal, Laura Thornton
+44-203-709-5700
helsinn@consilium-comms.com